etoposide has been researched along with amrubicin in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (38.10) | 29.6817 |
| 2010's | 11 (52.38) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Nokihara, H; Ohe, Y | 1 |
| Horiike, A; Saijo, N | 1 |
| Negoro, S | 1 |
| Hatashita, M; Hayashi, S; Jin, ZH; Kano, E; Matsumoto, H; Shioura, H | 1 |
| Fukuoka, Y; Hasegawa, Y; Hitsuda, Y; Igishi, T; Kodani, M; Kurai, J; Miyata, M; Shimizu, E; Suyama, H; Touge, H; Yasuda, K | 1 |
| Hanada, M; Noguchi, T; Yamaoka, T | 1 |
| Ariyoshi, Y; Fukuoka, M; Katakami, N; Kawahara, M; Negoro, S; Sawa, T; Sugiura, T; Takada, M; Takada, Y; Yamamoto, H; Yana, T; Yokota, S | 1 |
| Hann, CL; Rudin, CM | 1 |
| Baas, P; Bosquee, L; Bustin, F; Dingemans, AM; Fink, C; Hasan, B; Konopa, K; Lorigan, P; Margerit, S; Marshall, E; O'Brien, ME; Stigt, JA; Van Meerbeeck, J | 1 |
| Akamatsu, H; Endo, M; Kenmotsu, H; Murakami, H; Naito, T; Nakajima, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Wakuda, K; Yamamoto, N | 1 |
| Fukuoka, M; Horai, T; Katakami, N; Nakagawa, K; Ohmatsu, H; Okamoto, H; Saijo, N; Sekine, I; Shibuya, M; Yokoyama, A | 1 |
| Harada, M; Inoue, A; Ishida, T; Kinoshita, I; Maemondo, M; Mori, Y; Morikawa, N; Nakagawa, T; Nukiwa, T; Oizumi, S; Saito, R; Sugawara, S; Suzuki, T; Taima, K; Watanabe, H | 1 |
| Hirai, M; Kobayashi, Y; Konishi, T; Miyagawa, T; Nokubi, M; Saito, K; Washino, S | 1 |
| Cheng, Y; Feng, J; Han, B; Hao, X; Hou, M; Hu, C; Li, W; Liu, X; Liu, Y; Luo, X; Qin, S; Sun, Y; Wan, H; Wang, J; Xia, Z; Xiu, Q; Zhang, H; Zhang, L; Zhu, Y | 1 |
| Asao, T; Fujiwara, Y; Goto, Y; Horinouchi, H; Kanda, S; Kitahara, S; Nokihara, H; Ohe, Y; Okuma, HS; Sunami, K; Yamamoto, N | 1 |
| Fukui, T; Igawa, S; Katagiri, M; Kubota, M; Kurahayashi, S; Mitsufuji, H; Naoki, K; Nishinarita, N; Okuma, Y; Ono, T; Ozawa, T; Sasaki, J; Shirasawa, M; Sone, H; Sugimoto, A; Sugita, K | 2 |
| Azuma, K; Hoshino, T; Imamura, Y; Ishii, H; Kinoshita, T; Matsuo, N; Naito, Y; Tokito, T; Yamada, K | 1 |
| Nazha, B; Owonikoko, TK | 1 |
| Imai, H; Kagamu, H; Kaira, K; Kanazawa, K; Kishikawa, T; Minato, K; Minemura, H; Mouri, A; Nagai, Y; Shiihara, J; Shiono, A; Taniguchi, H; Tsuda, T; Wasamoto, S; Yamada, Y; Yamaguchi, O | 1 |
| Bando, Y; Fujisawa, M; Furukawa, J; Hara, T; Harada, K; Hirata, J; Jimbo, N; Nakano, Y; Okamura, Y; Terakawa, T; Ueki, H | 1 |
4 review(s) available for etoposide and amrubicin
| Article | Year |
|---|---|
[Recent progress in the treatment of ED small cell lung cancer].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Imatinib Mesylate; Irinotecan; Lung Neoplasms; Piperazines; Pyrimidines; Vincristine | 2002 |
Small-cell lung cancer: current therapy and novel agents.
Topics: Adult; Age Factors; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Etoposide; Humans; Irinotecan; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prognosis | 2005 |
[Treatment of small cell lung cancer].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Drug Administration Schedule; Etoposide; Humans; Irinotecan; Lung Neoplasms; Survival Analysis | 2005 |
Management of small-cell lung cancer: incremental changes but hope for the future.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Cranial Irradiation; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Practice Guidelines as Topic; Prognosis; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome | 2008 |
5 trial(s) available for etoposide and amrubicin
| Article | Year |
|---|---|
Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Salvage Therapy; Time Factors; Treatment Outcome | 2007 |
Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Etoposide; Europe; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome | 2011 |
A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Quality of Life; Small Cell Lung Carcinoma; Survival Rate | 2014 |
Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retreatment; Small Cell Lung Carcinoma; Survival Rate | 2015 |
Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; China; Cisplatin; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma | 2016 |
12 other study(ies) available for etoposide and amrubicin
| Article | Year |
|---|---|
Modification of thermosensitivity by amrubicin or amrubicinol in human lung adenocarcinoma A549 cells and the kinetics of apoptosis and necrosis induction.
Topics: Adenocarcinoma; Anthracyclines; Apoptosis; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Synergism; Etoposide; Hot Temperature; Humans; Lung Neoplasms; Necrosis; Time Factors | 2005 |
[A case of small-cell lung cancer effectively treated by bi-weekly administration of amrubicin].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2006 |
Amrubicin induces apoptosis in human tumor cells mediated by the activation of caspase-3/7 preceding a loss of mitochondrial membrane potential.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Caspase 7; Cell Division; Daunorubicin; Drug Therapy, Combination; Enzyme Activation; Etoposide; G2 Phase; Humans; Membrane Potentials; Mitochondria; Tumor Cells, Cultured; U937 Cells | 2006 |
Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Cohort Studies; Etoposide; Female; Humans; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Small Cell Lung Carcinoma; Time Factors; Topotecan; Treatment Outcome | 2015 |
[SMALL CELL CARCINOMA OF THE PROSTATE: A CASE REPORT OF RELATIVE LONG-TERM SURVIVAL].
Topics: Aged; Anthracyclines; Antineoplastic Agents; Carboplatin; Carcinoma, Small Cell; Etoposide; Fatal Outcome; Humans; Lymphatic Metastasis; Male; Multimodal Imaging; Positron-Emission Tomography; Prostatic Neoplasms; Time Factors; Tomography, X-Ray Computed | 2015 |
Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Young Adult | 2017 |
Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
Topics: Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Etoposide; Female; Health Status; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Thrombocytopenia | 2018 |
Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Paclitaxel; Recurrence; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2018 |
Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive-disease small cell lung cancer in the elderly and patients with poor performance status.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anthracyclines; Carboplatin; Etoposide; Female; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2018 |
The clinical conundrum of managing relapsed small cell lung cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Carboplatin; Clinical Decision-Making; Disease Progression; Etoposide; Humans; Immunoconjugates; Irinotecan; Liver Neoplasms; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Piperazines; Pyrimidines; Salvage Therapy; Small Cell Lung Carcinoma; Temozolomide; Thiourea; Topotecan | 2019 |
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Retrospective Studies; Small Cell Lung Carcinoma | 2022 |
Treatment outcome after sequential chemotherapy with cisplatin-etoposide, amrubicin and nogitecan in patients with treatment-related pure small-cell neuroendocrine prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2023 |